Clinical Trials Arena March 19, 2025
Discover the latest advancements in triple-negative breast cancer through Novotech CRO’s in-depth disease analysis.
A new report from leading global contract research organization Novotech examines the triple-negative breast cancer global clinical trial landscape in 2025, offering valuable insights into novel therapies, ongoing clinical trials, and future innovations shaping the treatment of triple-negative breast cancer, an aggressive and heterogeneous subtype of breast cancer, accounting for 10 to 15% of all breast cancer cases globally. Triple-negative breast cancer is characterized by the absence of estrogen receptors (ER), progesterone receptors (PR), and HER2 expression, limiting the effectiveness of targeted hormonal or HER2-directed therapies. The basal-like subtype dominates (~70%), associated with aggressive tumor biology.
According to the report, triple-negative breast cancer disproportionately affects younger...
Today's Sponsors
Today's Sponsor